12 unknown, 8 completed, 7 not yet recruiting, 6 recruiting. 14 Phase 2, 9 Phase 1, 9 Phase 3, 5 Not applicable, 2 Phase 4.
Follow Shandong New Time Pharmaceutical Co., LTD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) F520 combined with chemotherapy, placebo combined with chemotherapy - Cancer of Unknown Primary Site | Phase 2 / Phase 3 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 402 | 2026-07-08 | 2026-08-12 |
| Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors LNF2105(Antibody-Drug Conjugate (ADC) targeting Nectin-4) - Patients With Advanced Solid Tumors | Phase 1 | Not yet recruiting | Shandong New Time Pharmaceutical Co., LTD | 294 | 2026-06-01 | 2026-06-22 |
| A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 261 | 2026-01-25 | 2026-05-12 |
| F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus F182112 - Systemic Lupus Erythematosus (SLE) | Phase 1 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 64 | 2025-10-30 | 2026-09-21 |
| Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes F027, Ozempic® - Type 2 Diabetes (T2DM) | Phase 3 | Not yet recruiting | Shandong New Time Pharmaceutical Co., LTD | 496 | 2025-08-01 | 2025-07-01 |
| A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma F182112+P, F182112+CD38 - Relapsed or Refractory Multiple Myeloma | Phase 2 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 90 | 2025-07-02 | 2025-12-31 |
| A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents Valsartan Oral Solution, Placebo - Essential Hypertension | Phase 3 | Enrolling by invitation | Shandong New Time Pharmaceutical Co., LTD | 342 | 2025-02-05 | 2025-03-07 |
| Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding Vonorasan fumarate injection1, Vonorasan fumarate injection2, Esomeprazole sodium for injection - Peptic Ulcer Bleeding | Phase 2 | Not yet recruiting | Shandong New Time Pharmaceutical Co., LTD | 150 | 2025-02-01 | 2025-01-20 |
| A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors LNF2007 - Advanced Solid Tumors (Phase 1) | Phase 1 | Not yet recruiting | Shandong New Time Pharmaceutical Co., LTD | 94 | 2025-01-20 | 2024-12-30 |
| Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy CAPEOX, Placebo, AC591 - Colorectal Adenoma | Phase 2 | Not yet recruiting | Shandong New Time Pharmaceutical Co., LTD | 120 | 2024-12-01 | 2024-12-09 |
| A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction Mosapride Citrate Injection(high), Mosapride Citrate Injection(low), Placebo - Postoperative Gastrointestinal Dysfunction | Phase 2 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 150 | 2024-10-18 | 2025-01-20 |
| A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer Rulonilimab, Placebo, cisplatin/carboplatin + paclitaxel ± bevacizumab - Cervical Cancer | Phase 2 / Phase 3 | Enrolling by invitation | Shandong New Time Pharmaceutical Co., LTD | 510 | 2024-09-26 | 2025-01-01 |
| Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria Cetirizine Hydrochloride Injection, Diphenhydramine Hydrochloride Injection - Acute Urticaria | Phase 3 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 284 | 2024-04-22 | 2025-02-11 |
| Phase I Study of XZ120 in Malignant Tumors XZ120 injection - Advanced Malignancies | Phase 1 | Not yet recruiting | Shandong New Time Pharmaceutical Co., LTD | 123 | 2024-02-01 | 2024-01-16 |
| Phase I Study of LNF1901 in Advanced Malignant Tumors LNF1901 Monoclonal Antibody Injection - Advanced Malignant Tumors | Phase 1 | Not yet recruiting | Shandong New Time Pharmaceutical Co., LTD | 82 | 2024-02-01 | 2024-01-26 |
| Bioequivalence Study of Dronedarone Hydrochloride Tablets in Healthy Subjects Under Fasting Conditions Dronedarone Hydrochloride Tablets, MULTAQ® (Dronedarone Hydrochloride Tablets) - Atrial Fibrillation (AF) | Not applicable | Completed | Shandong New Time Pharmaceutical Co., LTD | 51 | 2023-06-05 | 2026-02-09 |
| Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans Nalfurafine Hydrochloride Orally Disintegrating Tablets, Remitch® - Pruritus | Not applicable | Completed | Shandong New Time Pharmaceutical Co., LTD | 72 | 2023-05-24 | 2026-03-17 |
| A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) F520, Pemetrexed, Carboplatin - Non-small Cell Lung Cancer, NSCLC | Phase 2 | Unknown | Shandong New Time Pharmaceutical Co., LTD | 84 | 2023-03-01 | 2023-02-24 |
| Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans Trifluridine and Tipiracil Tablets, Lonsurf® - Solid Tumor Cancer | Not applicable | Completed | Shandong New Time Pharmaceutical Co., LTD | 76 | 2022-11-21 | 2026-03-25 |
| Bioequivalence Study of Dronedarone Hydrochloride Tablets Dronedarone Hydrochloride Tablets, MULTAQ® (Dronedarone Hydrochloride Tablets) - Atrial Fibrillation (AF) | Not applicable | Completed | Shandong New Time Pharmaceutical Co., LTD | 48 | 2022-11-14 | 2026-02-09 |
Showing 20 of 35. Sign in to see all of them.
Multiple Myeloma (3) · Recurrence (3) · Atrial Fibrillation (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Diabetes Mellitus, Type 2 (1) · Essential Hypertension (1) · Lupus Erythematosus, Systemic (1) · Lymphoma (1) · Lymphoma, T-Cell, Peripheral (1) · Neoplasms, Unknown Primary (1) · Osteoporosis (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Peptic Ulcer Hemorrhage (1)
Carboplatin (2) · Dronedarone (2) · pomalidomide (2) · Bortezomib (1) · Capsules (1) · Cetirizine (1) · Cisplatin (1) · Dexamethasone (1) · Diphenhydramine (1) · Drug Therapy (1) · Esomeprazole (1) · Injections (1) · Orlistat (1) · Paclitaxel (1) · Pemetrexed (1)
China (24)
Guihua Wang, MD (1) · Xin Li, Doctor (1)